團隊負責人

張之昊，研究員。本科、碩士畢業于中國藥科大學，博士畢業于澳門科技大學，其後在美國密西西比大學、美國橡樹嶺國家實驗室從事博士後研究。長期從事腎髒藥理學、系統生物學和腸道微生物等領域的研究。以第一/通訊作者發表SCI論文31篇，包括Nature子刊Nature Communications（IF＝16.6, 最後通訊）1篇、Cell子刊Cell reports（IF＝7.5, 最後通訊）1篇、藥理領域權威期刊Pharmacological Research（IF＝9.3，共同通訊）1篇，Theranostics（IF＝12.4，共同通訊）1篇、Acta Pharmacol Sin（IF＝8.2，最後通訊/第一作者）2篇、Phytomedicine（IF＝7.9，最後通訊）1篇、Organic Letters（IF＝5.2，共同通訊）1篇等。總引用次數累計2000多次，申請國家發明專利7項，已授權2項。主持承擔國家自然科學基金1項、作為重要成員參與科技部重大新藥創制1項、教育部校雙一流建設項目1項，橫向科研項目3項。擔任The Innovation（IF＝32.1）等學術期刊青年編委。

1.團隊介紹

面向國家大健康戰略需求，團隊從事“中藥調控腸道菌群和代謝紊亂改善慢性腎病作用機制的研究”，以中醫藥整體觀和系統生物學理論為指導，以臨床樣本為基石、以組學分析為工具，以積雪草、大黃等中藥為研究對象，發展了“源于臨床、解碼成分、闡明機制”的基礎-臨床轉化研究模式，從腸道菌群和代謝穩态角度探索慢性腎病發生發展規律和中藥幹預下的轉歸效應與機制。

2.團隊研究方向

1) 基于代謝組學發現CKD診斷生物标志物；

2) 中藥及其活性成分抗慢性腎病作用靶點、作用機制研究；

3) 基于腸道菌群-内源性代謝物-抗慢性腎病的作用機制解析。

3.近期主要成果

1) Wei Zhou, Wen-hui Wu, Zi-lin Si, Hui-ling Liu, Hanyu Wang, Hong Jiang, Ya-fang Liu, Raphael N. Alolga, Cheng Chen, Shi-jia Liu, Xue-yan Bian, Jin-jun Shan, Jing Li, Ning-hua Tan*, Zhi-hao Zhang*, The gut microbe Bacteroides fragilis ameliorates renal fibrosis in mice, Nature communications, 2022, 13, 6081. doi:10.1038/s41467-022-33824-6. (IF = 17.694, 1區)

2) Zi-lin Si, Han-yu Wang, Tao Wang, Yi-zhi Cao, Qing-zhen Li, Kang Liu, Zhou Huang, Hui-ling Liu, Ya-jie Tan, Yin-yin Wang, Feng-qing Huang, Gao-xiang Ma, Raphael N. Alolga, Miao Yan, Cheng Chen, Jun-hui Li, Jing Li*, Hong-wei Liu*, Zhi-hao Zhang*. Gut Bacteroides ovatus ameliorates renal fibrosis by promoting the production of HDCA through upregulation of Clostridium scindens. Cell reports, 2024, 43(10), 114830. (IF = 8.8, 1區)

3) Ke Su, Bo Yi, Bi-qing Yao, Tian Xia, Yi-fei Yang, Zhi-hao Zhang, Cheng Chen, Liraglutide attenuates renal tubular ectopic lipid deposition in rats with diabetic nephropathy by inhibiting lipid synthesis and promoting lipolysis, Pharmacological Research, 2020, 156, 104778. (IF = 10.334, 1區)

4) Huachao Chen, Fei Li, Yongrong Yao, Zhe Wang, Zhihao Zhang, Ninghua Tan. Redox Dual-Responsive and O₂‑Evolving Theranostic Nanosystem for Highly Selective Chemotherapy against Hypoxic Tumor, Theranostics, 2019, 9 (1), 90-103. (IF = 11.600, 1區)

5) Wei Zhou, Min-min Chen, Hui-ling Liu, Zi-lin Si, Wen-hui Wu, Hong Jiang, Lin-xiao Wang, Nosratola D. Vaziri, Xiao-fei An, Ke Su, heng Chen, Ning-hua Tan and Zhi-hao Zhang, Dihydroartemisinin suppresses renal fibrosis in mice by nhibiting DNA-methyltransferase 1 and increasing Klotho, Acta Pharmacol Sin, 2022, 43(10), 2609-2623. (IF = 8.2, 1區)

6) Zhihao Zhang, Jun-Qiu He, Ying-Yong, Zhao, Huachao Chen, Ninghua Tan. Asiatic acid prevents renal fibrosis in UUO rats via promoting the production of 15d-PGJ2, an endogenous ligand of PPAR-γ. Acta Pharmacol Sin, 2020, 41, 373–382. (IF = 8.2, 1區)

7) Hui-ling Liu, Zhou Huang, Qing-zhen Li, Yi-zhi Cao, Han-yu Wang, Raphael N. Alolgab, Xue-yang Deng, Zhi-hao Zhang. Schisandrin A alleviates renal fibrosis by inhibiting PKCβ and oxidative stress. Phytomedicine, 2024, 155372. Doi: 10.1016/j.phymed.2024.155372 (IF = 7.9, 1區)

8) Hao Liang, Yun-Xing Ji, Rui-Han Wang, Zhi-Hao Zhang, and Bo Zhang. Visible-Light-Initiated Manganese-Catalyzed E-Selective Hydrosilylation and Hydrogermylation of Alkynes, Organic Letters, 2019, 21(8), 2750-2754. (IF = 6.072, 1區)

9) Zhihao Zhang, Zulfiqar Ali, Shabana I Khan, Ikhlas A. Khan*. Cytotoxic monacolins from red yeast rice, a Chinese medicine and food, Food Chemistry, 2016, 202, 262–268. (IF = 9.231, 1區)